With the common goal of improving the standard of care in women’s health, MedTech Innovator cohort members May Health, Bloomlife, and Madorra have developed novel technologies with a human-centric approach.
Welcome to MyStrategist, the digital home for MedTech Strategist.
MedTech Strategist, the global medical device industry's most trusted resource, will help you stay ahead of the opportunities and obstacles that are impacting your corporate strategy. We invite you to explore our coverage. Think Strategically. Subscribe TodayBrowse Latest Issue
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market PathwaysStart Trial
“Cut until it bleeds” is the rather crude and most effective treatment available to surgeons trying to debride deep infections occurring after orthopedic implant procedures and in people with infected diabetic foot ulcers. XTremedy’s mission is to successfully treat—and potentially prevent—surgical deep-tissue infections with pulsed field ablation.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.Learn More
Sinaptica began its commercial journey only recently, although its deep scientific underpinnings have already gotten it through a positive Phase II trial, which dramatically showed the benefit of a noninvasive neuromodulation therapy designed to achieve a network effect that slows disease progression in patients with mild to moderate Alzheimer’s.